Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 65   

Articles published

ARNA 4.34 -0.02 (-0.46%)
price chart
Arena Pharmaceuticals Price Target Sets Low Bar
Disclosure: I am long ARNA. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha).
Related articles »  
Is Arena The Next Alexion?
There was so much promise for the company and their recently approved drug Provenge that the valuation reached $6B for the company even before the product could hit the market. Many believers held the stock based on their ... Even though Alexion ...
Related articles »  
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) Fights for Share of Weight-loss Pill ...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA, ARNA message board) is expected to launch its patented Belviq treatment early next year, but there are some doubts that by that time Vivus, Inc. (NASDAQ:VVUS) will have made its Qsymia something of a ...
Related articles »  
Arena Pharmaceuticals, Vivus Inc, and the Weight-loss Craze
According to a Centers for Disease Control study earlier this year, about 36 percent of Americans are obese. While this might seem like an investing goldmine, biotech and small-cap pharmaceuticals are notoriously difficult companies to gauge. There are ...
Weight Loss Stocks In Action  Seeking Alpha
Related articles »  
Ampio's Promising Pipeline Could Send Company Higher
The following charts of Arena Pharmaceuticals (NASDAQ:ARNA), Amarin Corp (NASDAQ:AMRN) and Vivus, Inc. (NASDAQ:VVUS) show how rapidly prices can rise in the year before an approval.
Related articles »  
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug
In addition, Arena comes with some enticing benefits for a pharmaceutical suitor - 10 year Swiss Tax Haven and R&D Write-offs.
Related articles »  
Heroes And Zeros: Arena Pharmaceuticals And Avanir Pharmaceuticals
Arena Pharmaceuticals is a clinical stage biopharmaceutical company that has discovered, developed, and moved the first anti-obesity drug through FDA approval in the last 13 years in June of 2012.
500 Million Reasons to Bet on the Future of Mannkind (MNKD, ARNA,AMGN)
That is a huge show of strength for the diabetes drug developer operating in the biotech sector along with Amgen (NASDAQ: AMGN) and Arena Pharmaceuticals (NASDAQ: ARNA). As uber financier Mike Milken has pointed out, the ... that a good read was ...
Obesity Drugs Gain Attention on FDA Backing for Therapies
Third Rock Ventures is an early backer of Zafgen Inc., a biotechnology company in mid-stage trials of a therapy to treat obesity. The Food and Drug Administration cleared Belviq, from Arena Pharmaceuticals Inc. and Eisai Co., in June and Vivus Inc.'s ...
Vivus Shares Feel The Pain: Blockbuster Diet Drug Likely Won't Be Sold ...  Forbes
All Eyes On Vivus As Weight Loss Drug Hits Market  YCharts
Related articles »  
Promentis receives grant to develop schizophrenia drugs
Milwaukee-based Promentis Pharmaceuticals Inc. has received a three-year, $1.8 million award from the National Institutes of Health to develop more effective drugs to treat schizophrenia.